These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 9823775)

  • 1. High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains.
    Abdulkadir SA; Casolaro V; Tai AK; Thanos D; Ono SJ
    J Leukoc Biol; 1998 Nov; 64(5):681-91. PubMed ID: 9823775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression.
    Abdulkadir SA; Krishna S; Thanos D; Maniatis T; Strominger JL; Ono SJ
    J Exp Med; 1995 Aug; 182(2):487-500. PubMed ID: 7629508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter.
    Osborne AR; Zhang H; Fejer G; Palubin KM; Niesen MI; Blanck G
    J Biol Chem; 2004 Jul; 279(28):28911-9. PubMed ID: 15105429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional interaction between the POU domain protein Tst-1/Oct-6 and the high-mobility-group protein HMG-I/Y.
    Leger H; Sock E; Renner K; Grummt F; Wegner M
    Mol Cell Biol; 1995 Jul; 15(7):3738-47. PubMed ID: 7791781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation.
    Gstaiger M; Georgiev O; van Leeuwen H; van der Vliet P; Schaffner W
    EMBO J; 1996 Jun; 15(11):2781-90. PubMed ID: 8654375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. POU domain factors in neural development.
    Schonemann MD; Ryan AK; Erkman L; McEvilly RJ; Bermingham J; Rosenfeld MG
    Adv Exp Med Biol; 1998; 449():39-53. PubMed ID: 10026784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma.
    Wright KL; Ting JP
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7601-5. PubMed ID: 1502171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors.
    Zwilling S; König H; Wirth T
    EMBO J; 1995 Mar; 14(6):1198-208. PubMed ID: 7720710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of cis-linked regulatory sequences in the HLA DRA promoter by transcription in vitro.
    Hume CR; Lee JS
    Tissue Antigens; 1990 Sep; 36(3):108-15. PubMed ID: 2278044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.
    Osborne A; Zhang H; Yang WM; Seto E; Blanck G
    Mol Cell Biol; 2001 Oct; 21(19):6495-506. PubMed ID: 11533238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor interactions with Oct-1 and Brn-1 are physically and functionally distinct.
    González MI; Tovaglieri A; Robins DM
    Mol Cell Endocrinol; 2002 Apr; 190(1-2):39-49. PubMed ID: 11997177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Oct-1 POU domain mediates interactions between Oct-1 and other POU proteins.
    Verrijzer CP; van Oosterhout JA; van der Vliet PC
    Mol Cell Biol; 1992 Feb; 12(2):542-51. PubMed ID: 1346336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of Ets-2-induced transactivation of the tau interferon promoter by Oct-4.
    Ezashi T; Ghosh D; Roberts RM
    Mol Cell Biol; 2001 Dec; 21(23):7883-91. PubMed ID: 11689681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1.
    Murphy S
    Nucleic Acids Res; 1997 Jun; 25(11):2068-76. PubMed ID: 9153304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Segments of the POU domain influence one another's DNA-binding specificity.
    Aurora R; Herr W
    Mol Cell Biol; 1992 Feb; 12(2):455-67. PubMed ID: 1732727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The function of the octamer-binding site in the DRA promoter.
    Voliva CF; Jabrane-Ferrat N; Peterlin BM
    Immunogenetics; 1996; 43(1-2):20-6. PubMed ID: 8537118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes.
    Louis-Plence P; Moreno CS; Boss JM
    J Immunol; 1997 Oct; 159(8):3899-909. PubMed ID: 9378978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins.
    Schreiber E; Harshman K; Kemler I; Malipiero U; Schaffner W; Fontana A
    Nucleic Acids Res; 1990 Sep; 18(18):5495-503. PubMed ID: 2216722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1.
    Vigano MA; Staudt LM
    Nucleic Acids Res; 1996 Jun; 24(11):2112-8. PubMed ID: 8668543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription factor Oct-2A contains functionally redundant activating domains and works selectively from a promoter but not from a remote enhancer position in non-lymphoid (HeLa) cells.
    Müller-Immerglück MM; Schaffner W; Matthias P
    EMBO J; 1990 May; 9(5):1625-34. PubMed ID: 2328728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.